Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease.
van der Woude CJ, Stokkers P, van Bodegraven AA, Van Assche G, Hebzda Z, Paradowski L, D'Haens G, Ghosh S, Feagan B, Rutgeerts P, Dijkstra G, de Jong DJ, Oldenburg B, Farhan M, Richard T, Dean Y, Hommes DW; Initiative on Crohn's and Colitis, The Netherlands.
van der Woude CJ, et al. Among authors: van bodegraven aa, van assche g.
Inflamm Bowel Dis. 2010 Oct;16(10):1708-16. doi: 10.1002/ibd.21252.
Inflamm Bowel Dis. 2010.
PMID: 20848453
Clinical Trial.